Dynavax Technologies Stock Discussion

$Dynavax Technologies (DVAX.US)$
Dynavax Fights $950M Revenue Giant's Board Control: 300% Returns at Stake

$Dynavax Technologies (DVAX.US)$ Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
PR Newswire
EMERYVILLE, Calif., March 6, 2025
-- Opportunistic refinancing extends the maturity of most of existing debt
with improved terms and reduces dilution to existing capital structure
-- $225 million of convertible notes due in 2030 issued, including an
exchange for the retirement of $185 million of existing convertible
notes due in 2026 and $40 million of new money
-...

$Dynavax Technologies (DVAX.US)$
Record Revenue vs Board Control: Inside Dynavax's $714M Battle with Deep Track Capital

$Dynavax Technologies (DVAX.US)$
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
HEPLISAV-B revenue grew 26% YoY to $268 million in 2024
Q4 2024 revenue increased 39% YoY to $71 million
Strong cash position of $714 million
New $30 million DoD contract for plague vaccine development
Expected market expansion to $900 million by 2030 with 60% target market share
Negative
None.

$Dynavax Technologies (DVAX.US)$ Dynavax Awarded $30M Contract With U.S. Department of Defense >DVAX
Dow Jones· 3 mins ago

$Dynavax Technologies (DVAX.US)$
Dynavax Technologies Down Over 7%, On Track for Largest Percent Decrease Since August 2022 -- Data Talk
Dow Jones· 2 mins ago2mins
Dynavax Technologies Corporation ( DVAX ) is currently at $12.42, down $0.97 or 7.21%
--Would be lowest close since Nov. 7, 2024, when it closed at $12.02
--On pace for largest percent decrease since Aug. 17, 2022, when it fell 10.39%
--Currently down three of the past four days
--Currently down two consecutive days; down 8.1% ov...

$Dynavax Technologies (DVAX.US)$
Dynavax Announces $200 Million Share Repurchase Program
Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-Bachieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B...

📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen (AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb (BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies (DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...

$Dynavax Technologies (DVAX.US)$ Reuters· 1 min ago
Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B

$Dynavax Technologies (DVAX.US)$ Still on FDA PDUFA calendar today for sBLA 5/13/24